German drugmaker Merck KGaA (MKGAY.PK) and Pfizer Inc. (PFE) said Monday that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab alone or in combination with pegylated liposomal doxorubicin or PLD, a type of chemotherapy, compared with PLD did not meet the prespecified primary endpoints of overall survival (OS) or progression-free survival (PFS) in patients with platinum-resistant or -refractory ovarian cancer.
from RTT - Biotech https://ift.tt/2qRn4ow
via IFTTT
No comments:
Post a Comment